EQiTX forms immunotherapeutic subsidiary

By Lisa Kerner

Charlotte, N.C., June 27 - EQiTX Ltd. said it has restructured its synthetic vaccine project into a wholly owned company, ImmunoTX Pty. Ltd.

"The decision to form a new, fully owned immunotherapeutic company demonstrates the continuing commitment of EQiTX to immunotherapeutic vaccines," director Kevin Fahey said in a company news release.

"It is a positive development which will allow us to focus on diseases that are prioritized according to both commercial and scientific criteria."

Synthetic vaccines could be used to prevent or treat obesity, type 2 diabetes, atherosclerosis, cancers, allergies, and inflammatory and autoimmune disorders, the company said.

EQiTX is a Melbourne, Australia, biotechnology company specializing in chronic diseases and age-related conditions.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.